Intranasal Sendai Virus Vaccination of Seropositive Children 1 to 2 Years of Age in a Phase I Clinical Trial Boosts Immune Responses Toward Human Parainfluenza Virus Type 1
Intranasal SeV was well tolerated and uniformly immunogenic in seropositive children 1 to 2 years of age. Results encourage the further evaluation of SeV and SeV-based recombinants as potential intranasal vaccines for the prevention of infection by hPIV-1 and other serious respiratory pathogens.
Authors
- Allen Portner
- Randall T. Hayden (ORCID: https://orcid.org/0000-0002-3073-4115)
- Sherri L. Surman (ORCID: https://orcid.org/0000-0003-4199-661X)
- Kim Allison (ORCID: https://orcid.org/0000-0003-1344-1465)
- Rhiannon R. Penkert (ORCID: https://orcid.org/0000-0001-5317-1055)
- Kristen Branum
- Charles J. Russell (ORCID: https://orcid.org/0000-0001-5683-3990)
- Elisabeth E. Adderson (ORCID: https://orcid.org/0000-0001-9691-7814)
- Bart G. Jones
- Robert E. Sealy
- Karen S. Slobod
- Julia L. Hurwitz
Institutions
- St. Jude Children's Research Hospital (US)
- University of Oregon (US)
Publication Details
- Journal
- Vaccines
- Published
- 2025-04-19
- DOI
- https://doi.org/10.3390/vaccines13040430
- Citations
- 1
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- National Computational Infrastructure
- American Lebanese Syrian Associated Charities
- National Institute of Allergy and Infectious Diseases